Relugolix Patent Expiration
Relugolix is Used for the treatment of advanced prostate cancer in adult patients, specifically when the cancer is sex-hormone-dependent. It was first introduced by Sumitomo Pharma Switzerland Gmbh
Relugolix Patents
Given below is the list of patents protecting Relugolix, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Orgovyx | US10350170 | Solid preparation | Feb 25, 2036 | Sumitomo Pharma |
| Orgovyx | US10449191 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma |
| Orgovyx | US10786501 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma |
| Orgovyx | US11583526 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma |
| Orgovyx | US11795178 | Compositions of thienopyrimidine derivatives | Sep 27, 2033 | Sumitomo Pharma |
| Orgovyx | US7300935 | Thienopyrimidine compounds and use thereof | Jan 28, 2025 | Sumitomo Pharma |
| Orgovyx | US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | Jan 28, 2025 | Sumitomo Pharma |
| Orgovyx | US8735401 | Thienopyrimidine compounds and use thereof |
Feb 04, 2024
(Expired) | Sumitomo Pharma |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳